Palvella Therapeutics, Inc. cash flow to debt ratio of -3.95K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Palvella Therapeutics, Inc.'s free cash flow has decreased 130.68% from $-10.84M last year to $-25.01M, signaling decreasing performance

Palvella Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Palvella Therapeutics, Inc. has insufficient data to evaluate this check.

Palvella Therapeutics, Inc. has a net cash position, so leverage is healthy.

Palvella Therapeutics, Inc.'s interest coverage ratio is -7.60, which means that the company struggles to meet interest obligations, signaling financial risk.

Palvella Therapeutics, Inc. has insufficient data to evaluate this check.

Palvella Therapeutics, Inc.'s short-term assets of $58.99M exceed its short-term liabilities of $11.34M

Palvella Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Palvella Therapeutics, Inc.'s return on equity of -47.84%, is lower than 15.00%, indicating bad performance

Palvella Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Palvella Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Palvella Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Palvella Therapeutics, Inc. has negative free cash flow, indicating cash burn

Palvella Therapeutics, Inc.'s yearly earnings has decreased 139.27% since last year from $-17.43M to $-41.72M, signaling decreasing performance

Palvella Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -23.88% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Palvella Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Palvella Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Palvella Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Palvella Therapeutics, Inc. has insufficient data to evaluate this check.

Palvella Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Palvella Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Palvella Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Palvella Therapeutics, Inc. has insufficient data to evaluate this check.

Palvella Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Palvella Therapeutics, Inc. has a price-to-book ratio of 10.07x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Palvella Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue